Objective: Interaction of CA19-9 with E-selectin is involved in initiation of hematogenous metastases. We investigated whether serum concentrations of E-selectin and CA19-9 are good predictors of hematogenous metastases and prognosis in colorectal cancer.
Methods: Pre-operative serum samples were obtained from 152 patients with colorectal cancer, and from 28 healthy volunteers. Correlation between serum E-selectin and CA19-9 was studied in terms of clinically detected hematogenous metastases and prognosis of patients.
Results: Low serum concentration of E-selectin was defined as <50 U/ml in healthy volunteers, and on that basis, 20.4% of all patients belonged to the high E-selectin group. Several distinctive characteristics were observed in the clinical course of patients with high serum concentrations of both CA19-9 and E-selectin. The rate of Dukes' D cancer was significantly higher, and curative surgery was performed less frequently in patients with high serum concentrations of both CA19-9 and E-selectin (60 and 40%) than in others. However, there was no significant difference in the frequency of recurrence after curative surgery between patients with high serum concentrations of both CA19-9 and E-selectin (25.0%) and others. Overall the 5-year survival rate was significantly lower in patients with high serum concentrations of both CA19-9 and E-selectin (34.3%) than in other patients. Even if the serum concentration of CA19-9 was high, prognosis was not poor in patients with low serum concentration of E-selectin.
Conclusions: These results suggested that it was useful to measure both CA19-9 and E-selectin as markers of hematogenous metastases and as predictors of prognosis in colorectal cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/jjco/hyq095 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Depletion of β1,6-N-acetylglucosaminyltransferase reduces E-selectin binding capacity and migratory potential of human gastrointestinal adenocarcinoma cells.
Neoplasia
January 2025
Institute of Anatomy and Experimental Morphology, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, 20241, Hamburg, Germany; Institute of Anatomy I, Jena University Hospital, 07743, Jena, Germany; Comprehensive Cancer Center Central Germany (CCCG). Electronic address:
The commonly altered glycosylation of tumor cells is a hallmark of tumor progression and metastasis formation. One prominent example is the interaction of sialylated glycans at the tumor cell surface with endothelial (E)-selectin as an early event of an adhesion cascade that enables extravasation of circulating tumor cells (CTCs) into distant tissues. In a previous study, we identified GCNT3 (mucin-type core2/ core4 β1,6-N-acetylglucosaminyltransferase) highly over-expressed in gastrointestinal adenocarcinoma cells that facilitate the canonical E-selectin ligands sialyl-Lewis A and X (sLeA/X) for E-selectin binding and endothelial adhesion.
View Article and Find Full Text PDFCA19-9-Positive Extracellular Vesicle Is a Risk Factor for Cancer-Associated Thrombosis in Pancreatic Cancer.
Gastro Hep Adv
February 2024
Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Article Synopsis
- Cancer-associated venous thromboembolism (VTE) is a common and serious complication in cancer patients, especially those with pancreatic cancer, potentially linked to factors released by cancer cells.
- Researchers explored whether extracellular vesicles (EVs) carrying the glycan sialyl-Lewis, which is associated with the tumor marker CA19-9, contribute to the risk of VTE.
- The study found that higher levels of CA19-9 were linked to more instances of VTE, as CA19-9-positive EVs from cancer cells interact with E-selectin on endothelial cells, promoting heightened coagulation activity.
Tumor cell E-selectin ligands determine partialefficacy of bortezomib on spontaneous lung metastasis formation of solid human tumors in vivo.
Mol Ther
April 2022
Institute of Anatomy and Experimental Morphology, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
Article Synopsis
- Bortezomib (BZM), a proteasome inhibitor, reduces E-selectin levels in the lungs, preventing CTC adhesion and subsequent lung metastasis initiated by primary tumors.
- The effectiveness of BZM is influenced by the presence of high-affinity E-selectin ligands like sialyl-Lewis A (sLeA) and sLeX on tumor cells, which can limit BZM's ability to prevent metastasis.
- Tumor cells with low-affinity ligands still show reduced adhesion and metastasis when treated with BZM, but this effect vanishes when CD44 is knocked down or E-selectin is absent, highlighting the complex mechanisms of tumor cell adhesion.
Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter.
Biochim Biophys Acta Rev Cancer
April 2021
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, China; Department of Oncology, Shanghai Medical College, Fudan University, China; Pancreatic Cancer Institute, Fudan University, Shanghai Pancreatic Cancer Institute, China. Electronic address:
Carbohydrate antigen 19-9 (CA19-9) is the best validated biomarker and an indicator of aberrant glycosylation in pancreatic cancer. CA19-9 functions as a biomarker, predictor, and promoter in pancreatic cancer. As a biomarker, the sensitivity is approximately 80%, and the major challenges involve false positives in conditions of inflammation and nonpancreatic cancers and false negatives in Lewis-negative Individuals.
View Article and Find Full Text PDFE-selectin inhibition with GMI-1271 decreases venous thrombosis without profoundly affecting tail vein bleeding in a mouse model.
Thromb Haemost
June 2017
Daniel D. Myers, Jr., DVM, MPH, DACLAM, University of Michigan, North Campus Research Complex, Building 26, Room 263N, 2800 Plymouth Road, Ann Arbor, MI 48109-2800, USA, Tel.: +1 734 763 0940, E-mail:
Selectins, such as E-selectin (CD62E), function in venous thrombosis by binding and activating immune cells to initiate the coagulation cascade. GMI-1271 is a small molecule antagonist that inhibits E-selectin activity. Here we determine whether inhibition of E-selectin is sufficient to decrease acute venous thrombosis and associated inflammatory events in both prophylactic and treatment protocols without significantly affecting haemostasis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!